2024-520305-39-00招募中2 期
Efficacy and safety of minidosing lysergic acid diethylamide (LSD) for chronic cluster headache: a randomized placebo-controlled study
Radboud universitair medisch centrum Stichting3 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2025年1月21日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 52
- 试验地点
- 3
- 主要终点
- Mean change in weekly attack frequency in the third treatment week compared to the 4-week baseline, across treatment groups.
研究概览
简要总结
To evaluate the efficacy and safety of LSD 25μg every 3 days for 3 weeks in chronic cluster headache.
入排标准
- 年龄范围
- 0 years 至 65+ years（18-64 Years, 0-17 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •16-75 years of age at screening
- •Diagnosis of chronic cluster headache according to ICHD-3 criteria.
- •At the screening visit, a retrospective assessment of the 4 weeks prior to screening meets all of the following: An average of at least 8 attacks per week; Attack frequency in each week is within a 40% window around the average.
- •At the randomization visit, both of the following are met (inclusion criterion not to be shared with the subject): an average of at least 8 attacks per week; No absence of attacks on more than 2 consecutive days; Attack frequency in each week is within a 40% window around the average
- •Subject has signed informed consent; consent by proxy is not allowed.
- •Subject is aware of and willing to conform to all study procedures and visits.
- •Subjects are on a stable regimen of cluster headache prophylactics (defined in table 1 of study protocol) and agree not to increase the dose nor start a new cluster prophylactic during the screening and double-blind phase of the study.
- •Women of child-bearing potential must test negative for pregnancy at screening and start of treatment.
- •All females must agree either to abstain from sexual intercourse with a male partner, or to use of a reliable method of birth control during screening and treatment period as well as for 1 week after the last dose of study drug. Acceptable methods of birth control for this study include: oral contraceptives; implantable contraceptives; injectable contraceptives; a contraceptive patch; barrier methods such as diaphragms with contraceptive jelly, cervical caps with contraceptive jelly, condoms with contraceptive foam, or intrauterine devices; or a partner with vasectomy. Birth control is not required if the female is infertile due to surgical sterilization (hysterectomy, or at least 6 weeks after surgical bilateral oophorectomy or tubal ligation) confirmed by medical history or menopause. Menopause is defined as spontaneous amenorrhea for at least 12 months not induced by a medical condition.
排除标准
- •Known or suspected structural cause for cluster headache attacks (cluster-mimics).
- •Positive drug screen at screening.
- •History of cardiac valvular disease or disorder.
- •History or evidence of cognitive disorder at screening; MOCA <26 at screening.
- •History of significant and active medical comorbidities, including but not limited to hepatic, renal, urethral, vascular or cardiac valvular disease, cardiac rhythm disorders and hypertension (according to professional judgement).
- •Women who are pregnant or nursing.
- •Blood pressure at screening >160/100; pulse rate at screening >100 beats per minute.
- •eGFR at screening <60 ml/min.
- •Other headaches, if the patient cannot reliably distinguish them from attacks of cluster headache.
- •Current use of any of the prohibited prophylactic cluster headache treatments (defined in study protocol table 1), unless used under de conditions described in table 1 of the study protocol.
- •History of or actual psychotic or bipolar disorder; first degree relative(s) with (a history of) psychotic or bipolar disorder
- •A score of 6 or more on the ‘Ervaringenlijst’ (PQ-16).
- •History of suicidal intention or attempt and/or first degree relative with known history of suicidal intention or attempt.
- •The subject is at significant risk of suicide (at the at the discretion of the investigator or when in the C-SSRS a subject answers ‘yes’ to suicidal ideation questions 4 or 5 or to suicidal behaviour).
- •Active abuse of alcohol and/or any current use or severe past abuse of Schedule I listed drugs (Dutch: lijst 1 van de Opiumwet), at the discretion of the investigator (based on type of drug, reason for abuse (medical or non-medical), duration of abuse and abstinence, professional, relational and social impact, amongst others).
- •Medicinal or recreational use of cannabis, if any of the following applies: a score of ≥8 on the CUDIT-R is attained OR cannabis use within the 6 weeks prior to screening OR abstinence from using cannabis is refused for the duration of the study
结局指标
主要结局
Mean change in weekly attack frequency in the third treatment week compared to the 4-week baseline, across treatment groups.
Mean change in weekly attack frequency in the third treatment week compared to the 4-week baseline, across treatment groups.
次要结局
未报告次要终点
研究者
Prof. dr. Kees Kramers
Scientific
Radboud universitair medisch centrum Stichting
研究点 (3)
Loading locations...
相似试验
招募中
4 期
LOW DOse vs standard dose and administration TIme in near-infrared fluorescence cholangiography during laparoscopic cholecystectomy: a randomised clinical trial.2025-522535-33-00Fundacion Instituto De Estudios De Ciencias De La Salud De Castilla Y Leon122
招募中
2 期
The headache-inducing effects of sildenafil in men and women with episodic migraine without aura.Migraine without aura2024-512014-17-02Syddansk Universitet (University of Southern Denmark)27
招募中
2 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients with Angelman SyndromeAngelman syndrome2024-512589-32-00Ionis Pharmaceuticals Inc.4
招募中
3 期
A clinical trial to evaluate the effect of OTL-200, a gene therapy treatment in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)2024-511971-13-00Orchard Therapeutics (Europe) Limited6
尚未招募
2 期
Low-Dose Naltrexone For ME/CFS: Dose-FindingNCT07285473University of Alabama at Birmingham75